Compare Fox Corp Class A (FOXA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Sana Biotechnology Inc — how do they compare? Fox Corp Class A trades at $62.43 (market cap $24.58B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Fox Corp Class A is far larger — about 21.8× Sana Biotechnology Inc's market cap, and Fox Corp Class A pays a 0.93% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| FOXA | SANA | |
|---|---|---|
Market Cap | $24.58B | $1.13B |
Sector | Media | Health |
52-Week High | $76.11 | $5.92 |
52-Week Low | $48.79 | $2.68 |
Enterprise Value | $27.94B | $1.05B |
Dividend Yield | 0.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $63.05, down 0.58% today, with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.79 surpassing the $1.44 estimate, and revenue growth from $14.0B in 2024 to $16.3B in 2025. Recent news highlights World Cup-driven ad revenue and Tubi streaming growth as key catalysts.
The outlook is positive with a $65.33 consensus price target and 50% analyst buy ratings, but risks include declining 2026 net income projections and high RSI levels suggesting overbought conditions. The stock offers value with a P/E of 16.18 and robust cash flow, though investors should monitor sports cost pressures and debt levels.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
